NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
April 19, 2005 • Volume 2 / Number 16 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Gene Silencing Inhibits Tumors in Ewing's Sarcoma Model

Director's Update
Electricity and Excitement at AACR

Spotlight
Cancer Imaging: Pictures of the Future of Clinical Oncology

Cancer Research Highlights
Avastin with Taxol Slows Breast Cancer Progression

Celebrex Alters Gene Activity in the Colon

DLC-1 Gene Implicated in Prostate Cancer

Avastin, Immunotoxin Combo Shows Strong Anti-Tumor Effect

Statins Linked to Lower Risk of Advanced Prostate, Colon Cancer

Researchers Develop Models to Predict Metastatic Potential

A Conversation with
Drs. Denise Aberle and Christine Berg,
NLST Co-Directors


Notes
Gray to Lead NCI Extramural Activities

caBIG Meeting with Commercial Sector Planned

NCI Launches C-GEMS Project

Mirkin to Speak at Nanotech Seminar

CCR Grand Rounds

Community Update
Georgia Postal Service Rallies Support for Breast Cancer Research

Bulletin Archive

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Director's Update

Electricity and Excitement at AACR
NCI at AACR 2005
For more information about NCI presentations at the AACR annual meeting, go to http://www.cancer.gov/aacr2005.

Intellectual electricity is always evident at the meetings of the American Association for Cancer Research, but at the annual meeting that began on Saturday in Anaheim, there was also an aura of anticipation. Repeatedly, presentations of progress in cancer research were linked to prospects for improved cancer solutions.

In my presentation, I traced the trajectory that has led to the fusion of progress and purpose. I outlined the National Cancer Institute's (NCI's) commitment to leverage the investment of talent, time, and resources to further accelerate the elimination of the suffering and death due to cancer. Speakers such as Dr. Alfred Knudson, who received the AACR Lifetime Achievement Award, chronicled the exhilarating explosion of knowledge that led from observing cancer's mysterious behavior to now revealing cancer's molecular secrets.

Dr. von Eschenbach with AACR President Dr. Lynn Matrisian at the AACR annual meeting in Anaheim. Our nation's investment in cancer research, accelerated in 1971, has produced a golden era of progress, but it has also made possible a platinum future if we leverage the resources to match the opportunities. The intellectual electricity and the aura of anticipation evident at AACR will enrich our discovery-development-delivery strategy. Our emerging understanding of the molecular, cellular, and genetic mechanisms of the disease process has created an "inflection point" in cancer research, allowing us to make progress at an incredible pace.

Two important ways to leverage our investment in this effort are to promote Team Science and Big Science. Centers, consortia, and co-principal investigators are creating a culture of transdisciplinary collaborative research that will synergize science in the only way possible to address the unique complexity of cancer. Big Science that integrates science and technology will greatly accelerate the pace of progress in cancer research. This will, in turn, shorten the time it takes to advance from proof of concept to delivery of more effective interventions - from decades to years and from years to months.

We now have more resources devoted to cancer research than ever before. Today, 60 Cancer Centers, more than 4,000 principal investigators, and some of the most talented and brilliant scientists in the world are now simultaneously pursuing promising opportunities such as the integration of clinical research, bioinformatics, imaging, the human cancer genome, integrative systems biology, and nanotechnology.

Over the past 30 years, we have unraveled cancer's complexity and constructed a robust and dynamic cancer infrastructure. We must now nurture this new culture of cancer research to fully realize the fruits of the golden era of the National Cancer Program. By doing so, we can - and will - surge ahead toward a platinum future that is well within our grasp.

Dr. Andrew C. von Eschenbach
Director, National Cancer Institute

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov